News

Robin L. Rasor, Managing Director of Licensing at the Office of Technology Transfer of the University of Michigan, is planned to speak in the thrilling session “How to partner more efficiently with charities, foundations and patient groups”.

Speaking alongside Olivier Arnaud, European Research Director at JDRF and scheduled December 2nd at 9am, this second day’s first session promises to raise heated debates !

Robin shares with us today her feelings on the session :

“The University of Michigan has funding and relationships with many foundations, however, its relationship with the Leukemia and Lymphoma Foundation (LLS) has been considerably more collaborative than more traditional contracts.  In a recent partnership related to menin-MLL inhibitors with applications for treatment of leukemia and potentially other cancers, LLS provided cost sharing for some of the more expensive national stage patent filings as well as for CROs to do chemical synthesis under direction from the UM principal investigators, thereby freeing up their lab time for more inventive and creative endeavors.  In late 2014, UM licensed the portfolio to Kura Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines, which in addition to other typical financial terms also agreed to continue funding in the principal investigator’s lab.  Robin Rasor, Managing Director of Licensing at UM, will be prepared to discuss the pros and cons of such creative partnerships with foundations.”

Check out the full speakers list! 

Interested in speaking during BioFIT 2015 : contact us here

The summer promises to be hot…
and you are among those unlucky ones who spend it at your desk?

Cheer up! BioFIT team has great news for you!

How to implement and perform effective Due Diligence?

3 experts already confirmed their presence in this thrilling session!

Scheduled December 2^nd at 2pm, the session will raise crucial questions going with the Due Diligence process. Due diligence is a complex analysis of the commercial, legal and financial data that needs to be well prepared, how can a biotech company best prepare for this process? How long does the process last? What are the expectations on pharma’s side?

To answer these questions, 3 top-notch speakers already confirmed their presence:

• Cécile Théard-Jallu, partner at De Gaulle Fleurance et Associés, will speak alongside
• Martin Cadman, scientific Licensing Director at GlaxoSmithKline and
• Carl Jessop, Due Diligence Director at AstraZeneca to address this complex topic!

We are already looking forward to attending this promising session!

Want to speak at BioFIT? Contact Ramona Pirv-Chicireanu, Conference Coordinator

Getting close to the action: new collaborative models to source innovation

First session of BioFIT’s first day, this session already promises to be a very tasty appetizer!

You aren’t unaware that new models of partnerships and interactions have emerged in the life sciences industry: to address that challenging topic, analyze these new models strengths and challenges to be faced; look deeper at their organization, outcomes and successes, BioFIT Steering Committee selected once again the best speakers.

Therefore, will share their expertise in this session :

• Jon de Vlieger Call Director of the European lead Factory, TI Pharma
• Max Fehlmann CSO of Neomed
• Ulf Nerhbass Director of Ksilink
• Hitesh Sanganee Director in the Emerging Innovations group, Astrazeneca

Want to speak during BioFIT conference program ? Contact Ramona PIRV-CHICIREANU, conference coordinator.

Discover BioFIT in pictures, the leading partnering event in Europe for Open Innovation, technology transfer and collaborative public/private research in the field of Life Sciences.

Save money by registering before June 30^th! Register now